Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04535687
Other study ID # RCC-MUL-IIT-FZPL
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 17, 2020
Est. completion date June 12, 2023

Study information

Verified date June 2023
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial aims to prospectively assess the safety and efficiency of Fluzoparib in metastatic non-clear cell renal cell carcinoma


Recruitment information / eligibility

Status Completed
Enrollment 1
Est. completion date June 12, 2023
Est. primary completion date June 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility Inclusion Criteria: - Patients aged 18 years of age or older - Histological proof of metastatic non-clear cell renal cell carcinoma (AJCC Stage IV),Must have measurable disease as defined by RECIST 1.1 criteria - Somatic or germline mutation in homologous recombination gene from tissue, saliva or blood-based genetic test - At least one prior treatment with a Tyrosine Kinase Inhibitor,the progress of soft tissue lesions need to be consistent with RECIST1.1 - Any number of prior systemic therapies is allowed (cytokine, anti-angiogenic, mTOR, immune checkpoint blockage or clinical trial) - Participants must have a life expectancy = 3 months - ECOG PS = 1 - Participants must have normal organ and bone marrow function measured within 14 days prior to administration of study treatment as defined below: - Hemoglobin = 100 g/L - Absolute neutrophil count (ANC) = 1.5 x 10^9/L - Platelet count = 100 x 10^9/L - Total bilirubin = 1.5 x institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase (SGOT)) / Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT)) = 2.5 x institutional ULN - Blood Urea Nitrogen(BUN)/Creatinine(Cr)= 1.5 x institutional ULN - Appropriate measures should be taken for contraception for women in childbearing period and man with reproductive capacity - Willing and able to provide written informed consent. Exclusion Criteria: - Other malignancy unless curatively treated with no evidence of disease for = 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma. Patients with a history of localized triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy > 3 years prior to registration, and that the patient remains free of recurrent or metastatic disease - Patients with symptomatic uncontrolled brain metastases. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days. - Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT) - Judged by investigator, the subjects had other factors that could lead to the termination of the study such as with other serious disease (including mental illness) need to merge treatment, serious abnormal laboratory values, family and social factors maybe affect the safety or data collection - Breast feeding women - Use of any prohibited concomitant medications within the prior 2 weeks - Involvement in the planning and/or conduct of the study - Participation in another clinical study with an investigational product during the last 4 weeks - Patients receiving any systemic chemotherapy or radiotherapy within 4 weeks prior to study treatment - Any previous treatment with PARP inhibitor, including fluzoparib - Subjects Have failed to control the heart of the clinical symptoms or disease, such as: (1) the NYHA class II or worse heart failure;(2)unstable angina pectoris;(3)myocardial infarction occurred within 1 year;(4) Patients with clinically significant ventricular or ventricular arrhythmia requiring clinical intervention; (5) QTc=470ms - Concomitant use of known strong CYP3A inhibitors (e.g. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (e.g. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting fluzoparib is 2 weeks - Concomitant use of known strong CYP3A inducers (e.g. phenobarbital, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (e.g. bosentan, efavirenz, modafinil). The required washout period prior to starting fluzoparib is 5 weeks for phenobarbital or enzalutamide and 3 weeks for other agents - Adverse events caused by previously accepted treatment(except hair loss ) have not recovered (grade 1 or baseline level) or less - Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML - Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery - Unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication - Poor medical risk due to a serious, uncontrolled non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled uncontrolled major seizure disorder, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan - Congenital or acquired immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV) - Known hypersensitivity to fluzoparib or any of the excipients of the product - Known active hepatitis (i.e. Hepatitis B:HBsAg positive,HBV DNA=2000IU/ml or copy number=10000/ml;Hepatitis B:HCV antibodies positive,copy number=institutional ULN) - Uncontrolled hypertension, defined as systolic blood pressure (BP) >= 150 millimeters of mercury (mmHg) or diastolic BP >= 100 mmHg with or without antihypertensive dication - Packed red blood cells and/or platelet transfusions within the last 28 days prior to study entry - Abnormal coagulation function(INR>2.0,PT>16s),hemorrhagic tendency or undergoing thrombolytic or anticoagulant therapy. The patient can receive low dose aspirin, low molecular weight heparin for precausion

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fluzoparib
Fluzoparib

Locations

Country Name City State
China The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary objective response rate(ORR) the proportion of patients with CR, PR, and SD in the group(RECIST1.1) three months
Secondary radiographic progression free survival(rPFS) the time frame from the first day of fluzoparib to the date of radiographic confirmed progressive disease or death which one occurrs first six months
Secondary overall survival(OS) the time frame from the first day of fluzoparib to the date of death the time frame from the first day of apatinib to the date of death the time frame from the first day of apatinib to the date of death the time frame from the first day of apatinib to the date of death the time frame from the first day of apatinib to the date of death eighteen months
Secondary time to progression(TTP) the time frame from the first day of fluzoparib to the date of confirmed progressive six months
Secondary AE Number of Adverse Events, Grade 3 or higher as defined by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04987203 - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Phase 3
Recruiting NCT06391879 - Establishment of a Multidimensional Prediction Model for the Natural Course of VHL Disease-related Renal Cell Carcinoma
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Recruiting NCT04623502 - An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy N/A
Completed NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) Phase 2
Terminated NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma Phase 2
Completed NCT05070637 - Circulating Tumor Cell Reducing No-touch Nephrectomy N/A
Active, not recruiting NCT03634540 - A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Phase 2
Not yet recruiting NCT06049030 - A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT01358721 - Phase I Biomarker Study (BMS-936558) Phase 1
Active, not recruiting NCT04503148 - Anesthesia and Cancer Study: Renal Cell Carcinoma N/A
Completed NCT02386826 - INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme Phase 1
Not yet recruiting NCT05808608 - A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma Phase 1/Phase 2
Withdrawn NCT03323710 - Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma Phase 2
Completed NCT03052504 - Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy